Header Logo

Connection

Deborah Hall to Humans

Back to Details
This is a "connection" page, showing publications Deborah Hall has written about Humans.
Deborah Hall
Connection Strength
1.774
Humans
  1. Device-aided therapies for Parkinson's disease: "All for one, one for all, that is our device". Parkinsonism Relat Disord. 2023 Nov; 116:105862.
    View in: PubMed
    Score: 0.049
  2. An open label, non-randomized study assessing a prebiotic fiber intervention in a small cohort of Parkinson's disease participants. Nat Commun. 2023 02 18; 14(1):926.
    View in: PubMed
    Score: 0.047
  3. Gender Disparities in the Career of Neurology Researchers. Neurology. 2023 01 31; 100(5):e454-e464.
    View in: PubMed
    Score: 0.046
  4. Advance Directive Documentation in a Huntington's Disease Clinic: A Retrospective Chart Review. Tremor Other Hyperkinet Mov (N Y). 2022; 12:4.
    View in: PubMed
    Score: 0.044
  5. Comparison of motor, non-motor, and quality of life phenotype in Black and White patients with Parkinson's disease. Parkinsonism Relat Disord. 2022 03; 96:18-21.
    View in: PubMed
    Score: 0.044
  6. Parkinson's disease: Let food be thy medicine and medicine be thy food (Hippocrates). Parkinsonism Relat Disord. 2022 02; 95:113-114.
    View in: PubMed
    Score: 0.044
  7. Eye Movements in Fragile X-Associated Tremor/Ataxia Syndrome. J Neuroophthalmol. 2021 12 01; 41(4):e661-e664.
    View in: PubMed
    Score: 0.043
  8. Frequency of Parkinsonism and Parkinson Disease in African Americans in the Chicago Community. J Gerontol A Biol Sci Med Sci. 2021 06 14; 76(7):1340-1345.
    View in: PubMed
    Score: 0.042
  9. Mild Neurological Signs in FMR1 Premutation Women in an Unselected Community-Based Cohort. Mov Disord. 2021 10; 36(10):2378-2386.
    View in: PubMed
    Score: 0.042
  10. Genetic ataxias: update on classification and diagnostic approaches. Curr Neurol Neurosci Rep. 2021 02 26; 21(3):13.
    View in: PubMed
    Score: 0.041
  11. The Effects of Dual Task Cognitive Interference and Fast-Paced Walking on Gait, Turns, and Falls in Men and Women with FXTAS. Cerebellum. 2021 Apr; 20(2):212-221.
    View in: PubMed
    Score: 0.040
  12. Fragile X Gray Zone Alleles Are Associated With Signs of Parkinsonism and Earlier Death. Mov Disord. 2020 08; 35(8):1448-1456.
    View in: PubMed
    Score: 0.039
  13. Open-label pilot clinical trial of citicoline for fragile X-associated tremor/ataxia syndrome (FXTAS). PLoS One. 2020; 15(2):e0225191.
    View in: PubMed
    Score: 0.038
  14. Parkinson's Disease in African Americans: A Review of the Current Literature. J Parkinsons Dis. 2020; 10(3):831-841.
    View in: PubMed
    Score: 0.038
  15. Recruitment of patients with de novo Parkinson disease: successful strategies in a randomized exercise clinical trial. Trials. 2018 Nov 14; 19(1):630.
    View in: PubMed
    Score: 0.035
  16. Cognitive function impacts gait, functional mobility and falls in fragile X-associated tremor/ataxia syndrome. Gait Posture. 2018 10; 66:288-293.
    View in: PubMed
    Score: 0.035
  17. The state of clinical research in neurology. Neurology. 2018 04 10; 90(15):e1347-e1354.
    View in: PubMed
    Score: 0.034
  18. Fragile X syndrome and fragile X-associated tremor ataxia syndrome. Handb Clin Neurol. 2018; 147:377-391.
    View in: PubMed
    Score: 0.033
  19. Core Outcome Domains for early phase clinical trials of sound-, psychology-, and pharmacology-based interventions to manage chronic subjective tinnitus in adults: the COMIT'ID study protocol for using a Delphi process and face-to-face meetings to establish consensus. Trials. 2017 08 23; 18(1):388.
    View in: PubMed
    Score: 0.032
  20. A methylation PCR method determines FMR1 activation ratios and differentiates premutation allele mosaicism in carrier siblings. Clin Epigenetics. 2016; 8:130.
    View in: PubMed
    Score: 0.031
  21. Global cognitive function and processing speed are associated with gait and balance dysfunction in Parkinson's disease. J Neuroeng Rehabil. 2016 10 28; 13(1):94.
    View in: PubMed
    Score: 0.031
  22. Update on the Clinical, Radiographic, and Neurobehavioral Manifestations in FXTAS and FMR1 Premutation Carriers. Cerebellum. 2016 10; 15(5):578-86.
    View in: PubMed
    Score: 0.030
  23. Clinical Phenotype of Adult Fragile X Gray Zone Allele Carriers: a Case Series. Cerebellum. 2016 10; 15(5):623-31.
    View in: PubMed
    Score: 0.030
  24. Systematic review of outcome domains and instruments used in clinical trials of tinnitus treatments in adults. Trials. 2016 06 01; 17(1):270.
    View in: PubMed
    Score: 0.030
  25. Characterization and Early Detection of Balance Deficits in Fragile X Premutation Carriers With and Without Fragile X-Associated Tremor/Ataxia Syndrome (FXTAS). Cerebellum. 2015 Dec; 14(6):650-62.
    View in: PubMed
    Score: 0.029
  26. The consequences of tinnitus and tinnitus severity on cognition: A review of the behavioural evidence. Hear Res. 2016 Feb; 332:199-209.
    View in: PubMed
    Score: 0.029
  27. Fragile X gene expansions are not associated with dementia. Neurobiol Aging. 2014 Nov; 35(11):2637-2638.
    View in: PubMed
    Score: 0.026
  28. Evaluation of the acoustic coordinated reset (CR?) neuromodulation therapy for tinnitus: study protocol for a double-blind randomized placebo-controlled trial. Trials. 2013 Jul 10; 14:207.
    View in: PubMed
    Score: 0.024
  29. Clinical neurogenetics: fragile x-associated tremor/ataxia syndrome. Neurol Clin. 2013 Nov; 31(4):1073-84.
    View in: PubMed
    Score: 0.024
  30. Fragile X-associated tremor ataxia syndrome in FMR1 gray zone allele carriers. Mov Disord. 2012 Feb; 27(2):296-300.
    View in: PubMed
    Score: 0.022
  31. Executive dysfunction in young FMR1 premutation carriers: forme fruste of FXTAS or new phenotype? Neurology. 2011 Aug 16; 77(7):612-3.
    View in: PubMed
    Score: 0.021
  32. FMR1 gray-zone alleles: association with Parkinson's disease in women? Mov Disord. 2011 Aug 15; 26(10):1900-6.
    View in: PubMed
    Score: 0.021
  33. Pragmatic communication is impaired in Parkinson disease. Int J Neurosci. 2011 May; 121(5):254-6.
    View in: PubMed
    Score: 0.021
  34. FMR1 gene expansion and scans without evidence of dopaminergic deficits in parkinsonism patients. Parkinsonism Relat Disord. 2010 Nov; 16(9):608-11.
    View in: PubMed
    Score: 0.020
  35. Parkinsonism and cognitive decline in a fragile X mosaic male. Mov Disord. 2010 Jul 30; 25(10):1523-4.
    View in: PubMed
    Score: 0.020
  36. Shoulder pain in Parkinson's disease: a case-control study. Mov Disord. 2010 Jun 15; 25(8):1105-6.
    View in: PubMed
    Score: 0.020
  37. Tremor in 48,XXYY syndrome. Mov Disord. 2009 Oct 15; 24(13):2001-7.
    View in: PubMed
    Score: 0.019
  38. Movement disorders associated with aripiprazole use: a case series. Int J Neurosci. 2009; 119(12):2274-9.
    View in: PubMed
    Score: 0.018
  39. Parkinsonism in FMR1 premutation carriers may be indistinguishable from Parkinson disease. Parkinsonism Relat Disord. 2009 Feb; 15(2):156-9.
    View in: PubMed
    Score: 0.017
  40. Clinical science training at the University of Colorado: a measurement of trainee satisfaction. J Investig Med. 2007 May; 55(4):181-6.
    View in: PubMed
    Score: 0.016
  41. Paroxysmal nonkinesigenic dystonia and celiac disease. Mov Disord. 2007 Apr 15; 22(5):708-10.
    View in: PubMed
    Score: 0.016
  42. Symptomatic treatment in the fragile X-associated tremor/ataxia syndrome. Mov Disord. 2006 Oct; 21(10):1741-4.
    View in: PubMed
    Score: 0.015
  43. Maternal risk factors for term neonatal seizures: population-based study in Colorado, 1989-2003. J Child Neurol. 2006 Sep; 21(9):795-8.
    View in: PubMed
    Score: 0.015
  44. Adult nonketotic hyperglycinemia (NKH) crisis presenting as severe chorea and encephalopathy. Mov Disord. 2004 Apr; 19(4):485-6.
    View in: PubMed
    Score: 0.013
  45. Insight and Recommendations for Fragile X-Premutation-Associated Conditions from the Fifth International Conference on FMR1 Premutation. Cells. 2023 09 21; 12(18).
    View in: PubMed
    Score: 0.012
  46. Identification of genetic risk loci and causal insights associated with Parkinson's disease in African and African admixed populations: a genome-wide association study. Lancet Neurol. 2023 11; 22(11):1015-1025.
    View in: PubMed
    Score: 0.012
  47. Scales for Antipsychotic-Associated Movement Disorders: Systematic Review, Critique, and Recommendations. Mov Disord. 2023 06; 38(6):1008-1026.
    View in: PubMed
    Score: 0.012
  48. Integrated Multi-Cohort Analysis of the Parkinson's Disease Gut Metagenome. Mov Disord. 2023 03; 38(3):399-409.
    View in: PubMed
    Score: 0.012
  49. IN-HOME-PDCaregivers: The effects of a combined home visit and peer mentoring intervention for caregivers of homebound individuals with advanced Parkinson's disease. Parkinsonism Relat Disord. 2023 01; 106:105222.
    View in: PubMed
    Score: 0.012
  50. The Core Rehabilitation Outcome Set for Single-Sided Deafness (CROSSSD) study: International consensus on outcome measures for trials of interventions for adults with single-sided deafness. Trials. 2022 Sep 08; 23(1):764.
    View in: PubMed
    Score: 0.011
  51. IN-HOME-PD: The effects of longitudinal telehealth-enhanced interdisciplinary home visits on care and quality of life for homebound individuals with Parkinson's disease. Parkinsonism Relat Disord. 2022 09; 102:68-76.
    View in: PubMed
    Score: 0.011
  52. Mechanistic convergence across initiation sites for RAN translation in fragile X associated tremor ataxia syndrome. Hum Mol Genet. 2022 07 21; 31(14):2317-2332.
    View in: PubMed
    Score: 0.011
  53. Reply to: Cognitive Effects of Deep Brain Stimulation in GBA-Related Parkinson's Disease. Ann Neurol. 2022 08; 92(2):345-346.
    View in: PubMed
    Score: 0.011
  54. Soluble urokinase-type plasminogen activator receptor (suPAR) is elevated in caregivers of patients with parkinsonism. Parkinsonism Relat Disord. 2022 08; 101:39-42.
    View in: PubMed
    Score: 0.011
  55. The International Fragile X Premutation Registry: building a resource for research and clinical trial readiness. J Med Genet. 2022 12; 59(12):1165-1170.
    View in: PubMed
    Score: 0.011
  56. Gut microbial metabolites in Parkinson's disease: Association with lifestyle, disease characteristics, and treatment status. Neurobiol Dis. 2022 08; 170:105780.
    View in: PubMed
    Score: 0.011
  57. Gut-Brain Communication in Parkinson's Disease: Enteroendocrine Regulation by GLP-1. Curr Neurol Neurosci Rep. 2022 07; 22(7):335-342.
    View in: PubMed
    Score: 0.011
  58. Parkinson Disease and Subthalamic Nucleus Deep Brain Stimulation: Cognitive Effects in GBA Mutation Carriers. Ann Neurol. 2022 03; 91(3):424-435.
    View in: PubMed
    Score: 0.011
  59. Dopaminergic Therapy for Motor Symptoms in Early Parkinson Disease Practice Guideline Summary: A Report of the AAN Guideline Subcommittee. Neurology. 2021 11 16; 97(20):942-957.
    View in: PubMed
    Score: 0.011
  60. Characterization of the Cerebrospinal Fluid Proteome in Patients with Fragile X-Associated Tremor/Ataxia Syndrome. Cerebellum. 2022 Feb; 21(1):86-98.
    View in: PubMed
    Score: 0.010
  61. Identifying susceptibility genes for primary ovarian insufficiency on the high-risk genetic background of a fragile X premutation. Fertil Steril. 2021 09; 116(3):843-854.
    View in: PubMed
    Score: 0.010
  62. Timing of diffusion weighted imaging lesions in spontaneous intracerebral hemorrhage. J Neurol Sci. 2021 06 15; 425:117434.
    View in: PubMed
    Score: 0.010
  63. Systematic review of outcome domains and instruments used in designs of clinical trials for interventions that seek to restore bilateral and binaural hearing in adults with unilateral severe to profound sensorineural hearing loss ('single-sided deafness'). Trials. 2021 Mar 20; 22(1):220.
    View in: PubMed
    Score: 0.010
  64. Fretting-corrosion in hip taper modular junctions: The influence of topography and pH levels - An in-vitro study. J Mech Behav Biomed Mater. 2021 06; 118:104443.
    View in: PubMed
    Score: 0.010
  65. Association of Longitudinal Glycemia with Diffusion Weighted Imaging Lesions in Spontaneous Intracerebral Hemorrhage. J Stroke Cerebrovasc Dis. 2021 Mar; 30(3):105554.
    View in: PubMed
    Score: 0.010
  66. KICK OUT PD: Feasibility and quality of life in the pilot karate intervention to change kinematic outcomes in Parkinson's Disease. PLoS One. 2020; 15(9):e0237777.
    View in: PubMed
    Score: 0.010
  67. Understanding the relationship between freezing of gait and other progressive supranuclear palsy features. Parkinsonism Relat Disord. 2020 09; 78:56-60.
    View in: PubMed
    Score: 0.010
  68. Core Rehabilitation Outcome Set for Single Sided Deafness (CROSSSD) study: protocol for an international consensus on outcome measures for single sided deafness interventions using a modified Delphi survey. Trials. 2020 Mar 04; 21(1):238.
    View in: PubMed
    Score: 0.010
  69. Are the International Parkinson disease and Movement Disorder Society progressive supranuclear palsy (IPMDS-PSP) diagnostic criteria accurate enough to differentiate common PSP phenotypes? Parkinsonism Relat Disord. 2019 12; 69:34-39.
    View in: PubMed
    Score: 0.009
  70. Hypertension and progressive supranuclear palsy. Parkinsonism Relat Disord. 2019 09; 66:166-170.
    View in: PubMed
    Score: 0.009
  71. Authors' Response to "Barometric Pressure in Cerebral Amyloid Angiopathy: A Pressure to Bleed?" J Stroke Cerebrovasc Dis. 2019 06; 28(6):1782.
    View in: PubMed
    Score: 0.009
  72. The Influence of Weather on the Incidence of Primary Spontaneous Intracerebral Hemorrhage. J Stroke Cerebrovasc Dis. 2019 Feb; 28(2):405-411.
    View in: PubMed
    Score: 0.009
  73. Lifetime exposure to estrogen and progressive supranuclear palsy: Environmental and Genetic PSP study. Mov Disord. 2018 03; 33(3):468-472.
    View in: PubMed
    Score: 0.008
  74. Effect of High-Intensity Treadmill Exercise on Motor Symptoms in Patients With De Novo Parkinson Disease: A Phase 2 Randomized Clinical Trial. JAMA Neurol. 2018 02 01; 75(2):219-226.
    View in: PubMed
    Score: 0.008
  75. Anti-inflammatory drug use and progressive supranuclear palsy. Parkinsonism Relat Disord. 2018 03; 48:89-92.
    View in: PubMed
    Score: 0.008
  76. Factors Associated With Ambulatory Activity in De Novo Parkinson Disease. J Neurol Phys Ther. 2017 Apr; 41(2):93-100.
    View in: PubMed
    Score: 0.008
  77. Fragile X-associated tremor ataxia syndrome presenting as chronic fatigue syndrome. Parkinsonism Relat Disord. 2017 06; 39:85-86.
    View in: PubMed
    Score: 0.008
  78. Understanding falls in progressive supranuclear palsy. Parkinsonism Relat Disord. 2017 02; 35:75-81.
    View in: PubMed
    Score: 0.008
  79. Gait and Functional Mobility Deficits in Fragile X-Associated Tremor/Ataxia Syndrome. Cerebellum. 2016 08; 15(4):475-82.
    View in: PubMed
    Score: 0.008
  80. Fragile X-associated tremor/ataxia syndrome: phenotypic comparisons with other movement disorders. Clin Neuropsychol. 2016 Aug; 30(6):849-900.
    View in: PubMed
    Score: 0.008
  81. Relationship between uric acid levels and progressive supranuclear palsy. Mov Disord. 2016 05; 31(5):663-7.
    View in: PubMed
    Score: 0.007
  82. Environmental and occupational risk factors for progressive supranuclear palsy: Case-control study. Mov Disord. 2016 05; 31(5):644-52.
    View in: PubMed
    Score: 0.007
  83. Parkinsonism in fragile X-associated tremor/ataxia syndrome (FXTAS): revisited. Parkinsonism Relat Disord. 2014 Apr; 20(4):456-9.
    View in: PubMed
    Score: 0.006
  84. Implementation of a markerless motion analysis method to quantify hyperkinesis in males with fragile X syndrome. Gait Posture. 2014 Feb; 39(2):827-30.
    View in: PubMed
    Score: 0.006
  85. Study in Parkinson disease of exercise (SPARX): translating high-intensity exercise from animals to humans. Contemp Clin Trials. 2013 Sep; 36(1):90-8.
    View in: PubMed
    Score: 0.006
  86. Exercise for people in early- or mid-stage Parkinson disease: a 16-month randomized controlled trial. Phys Ther. 2012 Nov; 92(11):1395-410.
    View in: PubMed
    Score: 0.006
  87. Profile of functional limitations and task performance among people with early- and middle-stage Parkinson disease. Phys Ther. 2011 Sep; 91(9):1339-54.
    View in: PubMed
    Score: 0.005
  88. Improving fragile X-associated tremor/ataxia syndrome symptoms with memantine and venlafaxine. J Clin Psychopharmacol. 2010 Oct; 30(5):642-4.
    View in: PubMed
    Score: 0.005
  89. Adult-onset Alexander disease with progressive ataxia and palatal tremor. Mov Disord. 2008 Jan; 23(1):118-22.
    View in: PubMed
    Score: 0.004
  90. Cognitive profile of fragile X premutation carriers with and without fragile X-associated tremor/ataxia syndrome. Neuropsychology. 2008 Jan; 22(1):48-60.
    View in: PubMed
    Score: 0.004
  91. Treatment of fragile X-associated tremor ataxia syndrome (FXTAS) and related neurological problems. Clin Interv Aging. 2008; 3(2):251-62.
    View in: PubMed
    Score: 0.004
  92. Fragile X-associated tremor/ataxia syndrome: clinical features, genetics, and testing guidelines. Mov Disord. 2007 Oct 31; 22(14):2018-30, quiz 2140.
    View in: PubMed
    Score: 0.004
  93. Endurance exercise training to improve economy of movement of people with Parkinson disease: three case reports. Phys Ther. 2008 Jan; 88(1):63-76.
    View in: PubMed
    Score: 0.004
  94. Progression of tremor and ataxia in male carriers of the FMR1 premutation. Mov Disord. 2007 Jan 15; 22(2):203-6.
    View in: PubMed
    Score: 0.004
  95. Neuropathic features in fragile X premutation carriers. Am J Med Genet A. 2007 Jan 01; 143A(1):19-26.
    View in: PubMed
    Score: 0.004
  96. Abnormal elevation of FMR1 mRNA is associated with psychological symptoms in individuals with the fragile X premutation. Am J Med Genet B Neuropsychiatr Genet. 2005 Nov 05; 139B(1):115-21.
    View in: PubMed
    Score: 0.004
  97. Penetrance of the fragile X-associated tremor/ataxia syndrome in a premutation carrier population. JAMA. 2004 Jan 28; 291(4):460-9.
    View in: PubMed
    Score: 0.003
  98. Sonographic findings in patients with adenomyosis: can sonography assist in predicting extent of disease? AJR Am J Roentgenol. 2002 Aug; 179(2):379-83.
    View in: PubMed
    Score: 0.003
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.